AgomAb Therapeutics N.V. American Depositary Shares

AGMB

Biotechnology · Healthcare

Price

$12.04

-0.28 (-2.27%)

Market Cap

$592.9M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+34.5% over 3y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 36.2M (2022) → 48.7M (2025)

AgomAb Therapeutics is a clinical-stage biotechnology company focused on developing drugs to help the body repair damaged organs and tissues. Its main approach targets a biological pathway called HGF/MET, which plays a role in tissue regeneration and healing. The company is working on treatments for serious conditions like inflammatory bowel disease and organ fibrosis, where the body's normal repair process breaks down.

AgomAb does not yet sell any approved products, so it earns no revenue from sales. Instead, it funds its research through investor capital and potential partnership deals with larger pharmaceutical companies. The company is based in Belgium and operates primarily in Europe, with its shares also listed in the U.S. as American Depositary Shares. Its key risk is typical for early-stage biotech: it must successfully advance its drug candidates through expensive clinical trials before it can generate any commercial revenue, and failure in those trials would significantly impact the business.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-11.1% YoY

Earnings declining

R&D Spend

$49M/ year

↑ Rising (+24% vs prior year)

R&D investment increasing — building for the future

Insider Activity

26.4%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~2 years

$117M cash & investments

Quarterly Free Cash Flow

$117M cash & investments at current burn rate

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-12.6%

Weak — -12.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial